XXII

#5054
22nd Century Group, Inc - Common Stock
2.3 4 USD
-0.10%
Market Price
Settore: Beni di Consumo Difensivi
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.34
2.34
Intervallo Annuale
0.27
7.32
Variazione giornaliera
-10.34%
Variazione Mensile
-45.20%
Variazione di 6 mesi
-40.61%
Variazione Annuale
-58.95%
Chiusura Precedente
2.6 1
Open
2.3 4
Minimo
2.3 4
Massimo
2.3 4
Volume
1
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, 01 Sep 2026
22Nd Century Group, Inc. current report, 01 September 2026
8-K
Current report, Q3 FY2026
22Nd Century Group, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
22Nd Century Group, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
22Nd Century Group, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
22Nd Century Group, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
22Nd Century Group, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
22Nd Century Group, Inc. quarterly report, Q1 FY2026
10-Q

22Nd Century Group, Inc. current report, 24 January 2023

Full document

Business Context and Reporting Period

Company: 22nd Century Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 24, 2023
Reporting Period: Event date January 24, 2023

The Company, a Nevada corporation, operates in the cannabinoid sector. This filing serves as a Regulation FD disclosure regarding a strategic acquisition.

Key Financial Metrics

This Form 8-K is an event-driven report and does not contain audited financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.

Material Changes

  • Acquisition: On January 24, 2023, the Company announced the acquisition of RX Pharmatech Ltd (RXP).
  • Target Profile: RXP is a privately held distributor of cannabinoids based in the United Kingdom.
  • Strategic Impact: The acquisition expands the Company's distribution footprint into the UK market.

Guidance, Outlook, and Risks

Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the acquisition but does not provide specific financial guidance or quantitative outlooks within the text of the 8-K itself.

Risks and Contingencies: The report includes a standard forward-looking statements disclaimer. It notes that actual results may differ materially due to risks and uncertainties detailed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under "Risk Factors." The Company disclaims any obligation to update these statements.

Investor Verification Checklist

  • Verify the specific terms of the acquisition agreement with RX Pharmatech Ltd (RXP) in the attached press release (Exhibit 99.1).
  • Review the Company's most recent Form 10-K and 10-Q for detailed risk factors related to international expansion and M&A activities.
  • Confirm the regulatory status of RXP as a UK cannabinoid distributor and any pending regulatory approvals required for the transaction.
  • Monitor subsequent filings for the financial impact of the acquisition on the Company's balance sheet and cash flow.

Notizie